Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tutogen for sale

This article was originally published in The Gray Sheet

Executive Summary

Negotiations between Tutogen and an unnamed, "unaffiliated private equity firm" to acquire the company are expected to conclude by year-end, with due diligence to be completed by December, Tutogen says. Under a "non-binding" agreement announced Nov. 3, the equity firm has offered to purchase all outstanding Tutogen stock for $6 per share in cash - valuing the deal at about $94 mil. Tutogen has been seeking an acquirer to help grow sales of its Puros, Symmetry and PLIF specialty sterile allograft products (1"The Gray Sheet" May 5, 2003, p. 24). Zimmer, which acquired a 30% stake in Tutogen through its Centerpulse purchase earlier this year, says it is mulling the offer; however, a distribution pact with Tutogen will remain in place until expiration in 2010. Tutogen stock closed Nov. 4 at $5.59, up 23%...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT019314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel